• 1
    Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER 1985 The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 41:665676.
  • 2
    Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Suda T, Shultz LD, Nishikawa S 1990 The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442444.
  • 3
    Hofstetter W, Wetterwald A, Cecchini MC, Felix R, Fleisch H, Mueller C 1992 Detection of transcripts for the receptor for macrophage colony-stimulating factor, c-fms, in murine osteoclasts. Proc Natl Acad Sci USA 89:96379641.
  • 4
    Tanaka S, Takahashi N, Udagawa N, Tamura T, Akatsu T, Stanley ER, Kurokawa T, Suda T 1993 Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 91:257263.
  • 5
    Soriano P, Montgomery C, Geske R, Bradley A 1991 Targeted disruption of the c-src proto-oncogene leads to osteoporosis in mice. Cell 64:693702.
  • 6
    Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR 1992 Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 90:1622627.
  • 7
    Yoneda T, Niewolna M, Lowe C, Izbicka E, Mundy GR 1993 Hormonal regulation of pp60c-src expression during osteoclast formation in vitro. Mol Endocrinol 7:13131318.
  • 8
    Hall TJ, Schaeublin M, Missbach M 1994 Evidence that c-src is involved in the process of osteoclastic bone resorption. Biochem Biophys Res Commun 199:12371244.
  • 9
    Chappel J, Ross FP, Abu-Amer Y, Shaw A, Teitelbaum SL 1997 1,25-Dihydroxyvitamin D3 regulates pp60c-src activity and expression of a pp60c-src activating phosphatase. J Cell Biochem 67:432438.
  • 10
    Duong LT, Lakkakorpi PT Nakamura I, Machwate M, Nagy RM, Rodan GA 1998 PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of αvβ3 integrin, and phosphorylated by src kinase. J Clin Invest 102:881892.
  • 11
    Tanaka S, Amling M, Neff L, Peyman A, Uhlmann E, Levy JB, Baron R 1996 c-Cbl is downstream of c-Src in a signaling pathway necessary for bone resorption. Nature 383:528531.
  • 12
    Schwartzberg PL, Xing L, Hoffmann O, Lowell CA, Garrett L, Boyce BF, Varmus HE 1997 Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src−/− mutant mice. Genes Dev 11:28352844.
  • 13
    Wu L-W, Baylink DJ, Lau K-HW 1996 Molecular cloning and expression of a unique rabbit osteoclastic phosphotyrosyl phosphatase. Biochem J 316:515523.
  • 14
    Boyde A, Ali NN, Jones SI 1984 Resorption of dentine by isolated osteoclasts in vitro. Br Dent J 156:216220.
  • 15
    Tesuka K, Sato T, Kamioka H, Nijweide PJ, Tanaka K, Matsou T, Ohta M, Kurihara N, Hakeda Y, Kumegawa M 1992 Identification of osteopontin in isolated rabbit osteoclasts. Biochem Biophys Res Commun 186:911917.
  • 16
    Wu L-W, Yoon HK, Baylink DJ, Graves LM, Lau K-HW 1997 Fluoride at mitogenic doses induces a sustained activation of p44mapk, but not p42mapk, in human TE85 osteosarcoma cells. J Clin Endocrinol Metab 82:11261135.
  • 17
    Brickell PM 1992 The p60c-src family of protein-tyrosine kinases: Structure, regulation and function. Crit Rev Oncog 3:401446.
  • 18
    Hagenaars CE, Van Der Kraan AAM, Kawailrang-De Haas EWM, Visser JWM, Nijweide PJ 1989 Osteoclast formation from cloned hemopoietic stem cells. Bone Miner 6:179183.
  • 19
    Tanaka S, Takahashi N, Udagawa N, Sasaki T, Fukui Y, Kurokawa T, Suda T 1992 Osteoclasts express high levels of p60c-src, preferentially on ruffled border membranes. FEBS Lett 313:8589.
  • 20
    Blair HC, Jordan SE, Peterson TG, Barnes S 1996 Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J Cell Biochem 61:629637.
  • 21
    Missbach M, Jeschke M, Feyen J, Muller K, Glatt M, Green J, Susa M 1999 A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 24:437439.
  • 22
    Yoneda T, Lowe C, Lee C-H, Gutierrez G, Niewolna M, Williams PJ, Izbicka E, Uehara Y, Mundy GR 1993 Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclast bone resorption in vitro and hypercalcemia in vivo. J Clin Invest 91:27912795.
  • 23
    Lau K-HW, Karri S, Wu LW, Baylink DJ 1998 A unique osteoclastic phosphotyrosine phosphatase regulates c-src protein tyrosyl kinase activity in osteoclasts. Bone 23(Suppl):S190.(abstract 1175)
  • 24
    Thomas SM, Brugge JS 1997 Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513609.
  • 25
    Schwartzberg P 1998 The many faces of Src: Multiple functions of a prototypical tyrosine kinase. Oncogene 17:14631468.
  • 26
    Klinghoffer RA, Sachsenmaier C, Cooper JA, Soriano P 1999 Src family kinases are required for integrin but not PDGFR signal transduction. Eur Mol Biol Org 18:24592471.
  • 27
    Violette SM, Guan W, Bartlett C, Smith JA, Bardelay C, Antoine E, Rickles RJ, Mandine E, Van Schravendijk MR, Adams SE, Lynch BA, Shakespeare WC, Yang M, Jacobsen VA, Takeuchi CS, Macek KJ, Bohacek RS, Dalgarno DC, Weigele M, Lesuisse D, Sawyer TK, Baron R 2001 Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption. Bone 28:5464.